Crossbow Therapeutics is a biotech company that develops targeted therapies to address cancer antigens.
Crossbow Therapeutics has raised $77.0M in total funding. The most recent round was Series B. The last funding was announced in March 2026.
Crossbow Therapeutics's investors include Libbs Ventures, Eli Lilly, Polaris Partners, Sixty Degree Capital, MPM Capital.
Crossbow Therapeutics is headquartered in Cambridge, United States.
Crossbow Therapeutics is a biotech company that develops targeted therapies to address cancer antigens.
Crossbow Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Crossbow Therapeutics — Funding & Investors." VCBacked, March 18, 2026, https://www.vcbacked.co/company/crossbow-therapeutics. Accessed October 6, 2026.
VCBacked. (2026). Crossbow Therapeutics — Funding & Investors. Retrieved October 6, 2026, from https://www.vcbacked.co/company/crossbow-therapeutics
{{cite web |title=Crossbow Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/crossbow-therapeutics |website=VCBacked |access-date=October 6, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated